DWTX Key Statistics, Chart & Performance
The current stock price of DWTX is 4.07 USD. In the past month the price decreased by -37.58%. In the past year, price increased by 44.33%.
DWTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About DWTX
Company Profile
Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. The company is headquartered in Alpharetta, Georgia and currently employs 12 full-time employees. The company went IPO on 2020-12-17. The Company’s research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Nav 1.7 analgesic program is centered on its lead development candidate, Halneuron, which is a specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (CINP). The Company’s antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib for the treatment of fibromyalgia (FM) and Long-COVID (LC).
Company Info
DOGWOOD THERAPEUTICS INC
44 Milton Avenue
Alpharetta GEORGIA US
Employees: 12
Phone: 18666208655
DOGWOOD THERAPEUTICS INC / DWTX FAQ
What does DOGWOOD THERAPEUTICS INC do?
Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. The company is headquartered in Alpharetta, Georgia and currently employs 12 full-time employees. The company went IPO on 2020-12-17. The Company’s research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Nav 1.7 analgesic program is centered on its lead development candidate, Halneuron, which is a specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (CINP). The Company’s antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib for the treatment of fibromyalgia (FM) and Long-COVID (LC).
Can you provide the latest stock price for DOGWOOD THERAPEUTICS INC?
The current stock price of DWTX is 4.07 USD. The price decreased by -7.08% in the last trading session.
Does DWTX stock pay dividends?
DWTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of DWTX stock?
DWTX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is DWTX stock listed?
DWTX stock is listed on the Nasdaq exchange.
What is the employee count for DWTX stock?
DOGWOOD THERAPEUTICS INC (DWTX) currently has 12 employees.
When does DOGWOOD THERAPEUTICS INC (DWTX) report earnings?
DOGWOOD THERAPEUTICS INC (DWTX) will report earnings on 2026-03-30, after the market close.
DWTX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to DWTX. When comparing the yearly performance of all stocks, DWTX turns out to be only a medium performer in the overall market: it outperformed 67.71% of all stocks.
DWTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DWTX. No worries on liquidiy or solvency for DWTX as it has an excellent financial health rating, but there are worries on the profitability.
DWTX Financial Highlights
Over the last trailing twelve months DWTX reported a non-GAAP Earnings per Share(EPS) of -20.25. The EPS decreased by -209.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.46% | ||
| ROE | -51.66% | ||
| Debt/Equity | 0 |
DWTX Forecast & Estimates
8 analysts have analysed DWTX and the average price target is 18.7 USD. This implies a price increase of 359.46% is expected in the next year compared to the current price of 4.07.